https://orcid.org/0000-0003-4647-8088
![Sample our Behavioral Sciences journals, sign in here to start your access, latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/110801/TOC-Subject-Sample-2021-Behavioral-Sciences.jpg"})
"Psilocybin therapy for depression. A good trip?." Journal of Mental Health, 32(1), pp. 1–2
Disclosure statement
James Rucker leads the Psychoactive Trials Group at Kings College London, undertaking clinical trials with psilocybin and related compounds. Kings College London receives grant funding from Compass Pathways and Beckely PsyTech for clinical trials with psychedelics. James Rucker has no shareholdings in any pharmaceutical company.
Additional information
Funding
JR acknowledges funding (CS- 2017-17-007) from the National Institute for Health Research (NIHR) from 2018-2023. This work presents independent research part-funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. No award/grant number is applicable.